Biomarkers in Twin Pregnancies to Predict Preeclampsia and Preeclampsia-Related Complications

Biomarkers in Twin Pregnancies to Predict Preeclampsia and Preeclampsia-Related Complications - Biomarkers in Twin PE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49445

Enrollment

Registered

2020-12-16

Start date

2021-05-26

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Toxemia of Pregnancy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy Controls: - Women with a twin pregnancy - Age >= 18 years - No pre-existing hypertension, proteinuria, renal or other autoimmune disease - No suspicion of PE - No suspicion of fetal growth restriction - Gestational age >=20 weeks and = 18 years - Confirmed PE - Alive fetus without fetal distress requiring immediate delivery - Gestational age >= 20 weeks and

Exclusion criteria

Exclusion criteria: - The presence of fetal death at time of inclusion. - Pregnancy with a fetus affected by major congenital birth defects and/or chromosomal abnormalities - Unable to provide written informed consent.

Design outcomes

Primary

Measure	Time frame
1. PAPP-A2 and inhibin A levels in twin PE pregnancies versus twin healthy pregnancies. 2. PAPP-A2 and inhibin A levels in twin (healthy) pregnancies in comparison to singleton (healthy) pregnancies.	—

Secondary

Measure	Time frame
- Biomarker level course across gestational age (PAPP-A2, inhibin A, sFlt-1 and PlGF) in twin pregnancies in women with healthy vs. confirmed PE. - Correlation between PAPP-A2, inhibin A, sFlt-1 en PlGF levels in twin pregnancies.	—

Countries

Netherlands

Outcome results